First Moscow State Medical University Named after I.M.Sechenov (Sechenov University), 119991, Moscow, Russia.
Lomonosov Moscow State University, 119991, Russia, Moscow.
Curr Drug Targets. 2022;23(11):1099-1125. doi: 10.2174/1389450123666220418094853.
UNLABELLED: The gut microbiota are known to play an important role in maintaining the body's homeostasis and increasing its immunoresistance. Their role has not been well defined in the course of SARS-CoV-2 infection. AIM: The aim of this study was to evaluate the pathogenetic relationship between gut microbiota, immunological reactivity disruption and microbiota pathologies with the new coronavirus infection's course in order to substantiate the use of current drugs correcting gut microbiota during the SARS-CoV-2 pandemic. MATERIALS AND METHODS: Electronic databases of WHO Infection Control, Global Health, ScienceDirect, Elsevier, CDC infection diseases database, Google Academy, "Scientific electronic library eLIBRARY.RU", MEDLINE, CyberLeninka, Embase, PubMed-NCBI, RSCI, Scopus, and Cochrane Library were used for this analytical research. RESULTS: The research results showed normal gut microbiota as one of the important components of a multilevel immune defense system. The intestinal microbiota support the notion of initial activation and readiness in order to induce a quick response to the invasion of pathogens, including RNA viruses, such as SARS-CoV-2. Current research suggests that the intestinal microbiota play an important role in the pathogenesis and predetermination of disease severity in COVID-19. By producing essential metabolites and neutralizing toxic substrates, symbionts regulate the functioning of all organs and systems, maintaining the body's homeostasis and immunological responses. Intestinal microbiota disorders determine the postvaccination anti-COVID immunity's efficacy, specifically the susceptibility to SARS-CoV-2 and the severity of this infection. This is done by stimulating a local intestinal immune response via secretory immunoglobulins and the acquired immunity of the microbiome. The high prevalence of dysbiosis within the populous indicates the necessity of regular gut microbiota biocorrection during the SARS-CoV-2 pandemic. Our systematic review of current biopreparations correcting gut microbiota provides a valuable reference to the practicing clinicians to quickly specify and develop a wide variety of medicines, assess their capabilities, and choose the optimal treatment for patients at risk of SARS-CoV-2 infection. CONCLUSION: Current data support the notion that gut microflora biocorrection may help increase population immunity and preserve public health during the SARS-CoV-2 pandemic.
未加标签:肠道微生物群被认为在维持身体内环境平衡和提高其免疫抵抗力方面发挥着重要作用。它们在 SARS-CoV-2 感染过程中的作用尚未得到很好的定义。
目的:本研究旨在评估肠道微生物群、免疫反应紊乱和微生物群病理学与新型冠状病毒感染过程之间的发病关系,以证实在 SARS-CoV-2 大流行期间使用当前纠正肠道微生物群的药物。
材料和方法:本分析性研究使用了世界卫生组织感染控制、全球健康、ScienceDirect、爱思唯尔、疾病控制与预防中心传染病数据库、谷歌学术、“科学电子图书馆 eLIBRARY.RU”、MEDLINE、CyberLeninka、Embase、PubMed-NCBI、RSCI、Scopus 和 Cochrane 图书馆的电子数据库。
结果:研究结果表明,正常的肠道微生物群是多层次免疫防御系统的重要组成部分之一。肠道微生物群支持初始激活和准备的概念,以便对包括 SARS-CoV-2 在内的 RNA 病毒的入侵快速做出反应。目前的研究表明,肠道微生物群在 COVID-19 的发病机制和疾病严重程度的预测中发挥着重要作用。共生微生物通过产生必需代谢物和中和有毒底物来调节所有器官和系统的功能,维持身体的内环境平衡和免疫反应。肠道微生物群紊乱决定了 COVID-19 疫苗接种后的抗 COVID 免疫力的效果,特别是对 SARS-CoV-2 的易感性和这种感染的严重程度。这是通过通过分泌免疫球蛋白和微生物组的获得性免疫来刺激局部肠道免疫反应来实现的。在人群中,肠道微生态失调的高流行率表明,在 SARS-CoV-2 大流行期间,需要定期进行肠道微生物群生物矫正。我们对当前纠正肠道微生物群的生物制剂的系统评价为临床医生提供了有价值的参考,以快速确定和开发各种药物,评估它们的能力,并为有 SARS-CoV-2 感染风险的患者选择最佳治疗方案。
结论:现有数据支持肠道微生物群生物矫正可能有助于在 SARS-CoV-2 大流行期间提高人群免疫力和保护公共卫生的观点。
Virus Res. 2020-5-13
Gastroenterology. 2020-5-20
Front Cell Infect Microbiol. 2023
World J Gastroenterol. 2022-12-21
Front Cell Infect Microbiol. 2020
Viruses. 2022-5-30